OBJECTIVES: To compare EQ-5D and SF-6D utilities across groups of chronic heart failure (CHF) patients with varying levels of disease severity. METHODS: A consecutive sample (N = 251) of CHF patients undergoing elective cardiac surgery were surveyed. Disease severity was proxied via a self-assessment scale, the EQ-VAS and the Duke Activity Status Index (DASI); however, validity was demonstrated only by the latter. Association and level of agreement between instruments in DASI-based severity groups were estimated with Pearson's r and the intraclass correlation coefficient (ICC), respectively. Paired-samples t test was used to identify significant differences. In a linear regression model, the DASI was used as an anchor of disease severity to identify a potential "crossover" point between EQ-5D and SF-6D utilities. RESULTS: EQ-5D and SF-6D strongly correlated over the entire sample (r = 0.647, P < 0.001); however, their agreement was moderate (ICC = 0.484, P < 0.001). In the less severe DASI groups (i.e. higher functional capacity) EQ-5D was significantly higher than SF-6D (P < 0.001) and differences constituted minimally important differences (MIDs). Contrarily, in the more severe groups SF-6D was predominantly higher than EQ-5D. The regression model indicated a utility crossover point at 0.722 and predicted that individuals with a utility score less than this would score higher on the SF-6D than on the EQ-5D, and vice versa. The DASI score at crossover was calculated at 31.94. CONCLUSIONS: In subgroups of patients differing in CHF severity according to the DASI, mean EQ-5D and SF-6D indices differed significantly. Contrarily, in socio-demographic and clinical groups, these utility differences were not directly evident. According to the evidence, comparisons based on severity classification via a valid disease-specific external instrument may provide insight on instrument choice in cost-utility analyses.
OBJECTIVES: To compare EQ-5D and SF-6D utilities across groups of chronic heart failure (CHF) patients with varying levels of disease severity. METHODS: A consecutive sample (N = 251) of CHFpatients undergoing elective cardiac surgery were surveyed. Disease severity was proxied via a self-assessment scale, the EQ-VAS and the Duke Activity Status Index (DASI); however, validity was demonstrated only by the latter. Association and level of agreement between instruments in DASI-based severity groups were estimated with Pearson's r and the intraclass correlation coefficient (ICC), respectively. Paired-samples t test was used to identify significant differences. In a linear regression model, the DASI was used as an anchor of disease severity to identify a potential "crossover" point between EQ-5D and SF-6D utilities. RESULTS: EQ-5D and SF-6D strongly correlated over the entire sample (r = 0.647, P < 0.001); however, their agreement was moderate (ICC = 0.484, P < 0.001). In the less severe DASI groups (i.e. higher functional capacity) EQ-5D was significantly higher than SF-6D (P < 0.001) and differences constituted minimally important differences (MIDs). Contrarily, in the more severe groups SF-6D was predominantly higher than EQ-5D. The regression model indicated a utility crossover point at 0.722 and predicted that individuals with a utility score less than this would score higher on the SF-6D than on the EQ-5D, and vice versa. The DASI score at crossover was calculated at 31.94. CONCLUSIONS: In subgroups of patients differing in CHF severity according to the DASI, mean EQ-5D and SF-6D indices differed significantly. Contrarily, in socio-demographic and clinical groups, these utility differences were not directly evident. According to the evidence, comparisons based on severity classification via a valid disease-specific external instrument may provide insight on instrument choice in cost-utility analyses.
Authors: F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: Nick Kontodimopoulos; Evelina Pappa; Angelos A Papadopoulos; Yannis Tountas; Dimitris Niakas Journal: Qual Life Res Date: 2008-11-29 Impact factor: 4.147
Authors: Garry R Barton; Tracey H Sach; Anthony J Avery; Claire Jenkinson; Michael Doherty; David K Whynes; Kenneth R Muir Journal: Health Econ Date: 2008-07 Impact factor: 3.046
Authors: John T Parissis; Maria Nikolaou; Dionysia Birmpa; Dimitrios Farmakis; Ioannis Paraskevaidis; Vassiliki Bistola; Theodoros Katsoulas; Gerasimos Filippatos; Dimitrios T Kremastinos Journal: Am J Cardiol Date: 2008-10-17 Impact factor: 2.778
Authors: Gian Luca Di Tanna; Michael Urbich; Heidi S Wirtz; Barbara Potrata; Marieke Heisen; Craig Bennison; John Brazier; Gary Globe Journal: Pharmacoeconomics Date: 2020-11-30 Impact factor: 4.981